Association of Maternal Medical Comorbidities with Duration of Expectant Management in Patients with Severe Preeclampsia
- PMID: 37072011
- PMCID: PMC10582202
- DOI: 10.1055/s-0043-1768232
Association of Maternal Medical Comorbidities with Duration of Expectant Management in Patients with Severe Preeclampsia
Abstract
Objective: This study aimed to estimate the association between number of maternal comorbidities and duration of expectant management and perinatal outcomes in patients with preeclampsia with severe features.
Study design: Retrospective cohort of patients with preeclampsia with severe features delivering live, nonanomalous singletons at 23 to 342/7 weeks' gestation at a single center from 2016 to 2018. Patients delivered for an indication other than severe preeclampsia were excluded. Patients were categorized based on the number (0, 1, or ≥2) of comorbidities present: chronic hypertension, pregestational diabetes, chronic kidney disease, and systemic lupus erythematosus. The primary outcome was proportion of potential expectant management time achieved, that is, days of expectant management achieved divided by total potential expectant management time (days from severe preeclampsia diagnosis to 340/7 weeks). Secondary outcomes included delivery gestational age, days of expectant management, and perinatal outcomes. Outcomes were compared in bivariable and multivariable analyses.
Results: Of 337 patients included, 167 (50%) had 0, 151 (45%) had 1, and 19 (5%) had ≥2 comorbidities. Groups differed with respect to age, body mass index, race/ethnicity, insurance, and parity. The median proportion of potential expectant management achieved in this cohort was 1.8% (interquartile range: 0-15.4), and did not differ by number of comorbidities (adjusted β: 5.3 [95% confidence interval [CI]: -2.1 to 12.9] for 1 comorbidity vs. 0 and adjusted β: -2.9 [95% CI: -18.0 to 12.2] for ≥2 comorbidities vs. 0). There was no difference in delivery gestational age or duration of expectant management in days. Patients with ≥2 (vs. 0) comorbidities had higher odds of composite maternal morbidity (adjusted odds ratio: 3.0 [95% CI: 1.1-8.2]). There was no association between number of comorbidities and composite neonatal morbidity.
Conclusion: Among patients with preeclampsia with severe features, the number of comorbidities was not associated with duration of expectant management; however, patients with ≥2 comorbidities had higher odds of adverse maternal outcomes.
Key points: · Greater number of medical comorbidities were not associated with expectant management duration.. · Two or more medical comorbidities were associated with higher odds of adverse maternal outcomes.. · Expectant management should be undertaken cautiously in medically complicated patients..
Thieme. All rights reserved.
Conflict of interest statement
None declared.
Figures
Similar articles
-
Amount of Proteinuria and Duration of Expectant Management in Severe Preeclampsia.Am J Perinatol. 2024 Apr;41(6):790-797. doi: 10.1055/s-0042-1748524. Epub 2022 May 29. Am J Perinatol. 2024. PMID: 35644128
-
Quantifying the additional maternal morbidity in women with preeclampsia with severe features in whom immediate delivery is recommended.Am J Obstet Gynecol MFM. 2022 May;4(3):100565. doi: 10.1016/j.ajogmf.2022.100565. Epub 2022 Jan 13. Am J Obstet Gynecol MFM. 2022. PMID: 35033750
-
Expectant management of preeclampsia with severe features diagnosed at less than 24 weeks.Am J Obstet Gynecol. 2025 Feb;232(2):212.e1-212.e8. doi: 10.1016/j.ajog.2024.04.031. Epub 2024 Apr 30. Am J Obstet Gynecol. 2025. PMID: 38697342
-
Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis.Am J Obstet Gynecol. 2022 Aug;227(2):218-230.e8. doi: 10.1016/j.ajog.2022.04.034. Epub 2022 Apr 26. Am J Obstet Gynecol. 2022. PMID: 35487323 Review.
-
Delivery or expectant management for prevention of adverse maternal and neonatal outcomes in hypertensive disorders of pregnancy: an individual participant data meta-analysis.Ultrasound Obstet Gynecol. 2019 Apr;53(4):443-453. doi: 10.1002/uog.20224. Ultrasound Obstet Gynecol. 2019. PMID: 30697855 Free PMC article.
References
-
- Sibai BMPublications Committee, Society for Maternal-Fetal Medicine. Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 2011;205(03):191–198 - PubMed
-
- Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancy 2009;28(03):312–347 - PubMed
-
- Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28–34 weeks’ gestation: a randomized controlled trial. Obstet Gynecol 1990;76(06):1070–1075 - PubMed
-
- Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial. Am J Obstet Gynecol 1994;171(03):818–822 - PubMed
-
- Vigil-De Gracia P, Reyes Tejada O, Calle Miñaca A, et al. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial. Am J Obstet Gynecol 2013;209(05):425.e1–425.e8 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources